Shanghai Fosun Pharmaceutical (600196.SH): HLX18 approved for Phase I clinical trial for treatment of various solid tumors.

17:00 20/03/2026

Fosun Pharma (600196.SH) announced that its controlling subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd. and its subsidiary (collectively "Fuhong Hanlin"), have received approval from the National Medical Products Administration to conduct phase I clinical trials for HLX18 (a recombinant anti-PD-1 humanized monoclonal antibody injection) for the treatment of multiple solid tumors. Fuhong Hanlin plans to conduct relevant clinical studies for this drug in China as soon as the conditions are met.

Shanghai Fosun Pharmaceutical (600196.SH) announced that its controlling subsidiary, Shanghai HENLIUS Biotech Co., Ltd. and its subsidiaries (collectively "HENLIUS"), have received approval from the National Medical Products Administration to conduct Phase I clinical trials for HLX18 (recombinant anti-PD-1 monoclonal antibody injection) for the treatment of multiple solid tumors. HENLIUS plans to conduct the relevant clinical studies for this drug in China once conditions are met.

Shanghai Fosun Pharmaceutical (02196): Sodium Thiosulfate Injection Approved for Registration

Yum China (09987) spent HK$7.712 million on March 19 to repurchase 18,200 shares.

XIAOMI-W (01810) spent 99.99 million Hong Kong dollars to repurchase 2.975 million shares on March 20th.

Shanghai Fosun Pharmaceutical (02196): Sodium Thiosulfate Injection Approved for Registration

Yum China (09987) spent HK$7.712 million on March 19 to repurchase 18,200 shares.

XIAOMI-W (01810) spent 99.99 million Hong Kong dollars to repurchase 2.975 million shares on March 20th.